Joseph Ahn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joseph Ahn has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Ho Joong Choi
Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
7 shared publications - Young Kyoung You
Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
6 shared publications - Chang Ho Seo
Department of Surgery, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
4 shared publications Tae Ho Hong
Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea
4 shared publications- Ha-Eun Hong
Department of Surgery, Seoul ST. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
3 shared publications - Ok-Hee Kim
Catholic Central Laboratory of Surgery, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
3 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 108 (3) , 186-197
Scaffold implantation vs. intravenous delivery: a comparative preclinical animal study evaluating peroxisome proliferator-activated receptor gamma coactivator 1-alpha adipose-derived stem cells in liver fibrosis treatment
Regenerative medicine is expected to offer an alternative to liver transplantation for treating liver diseases in the future, with one significant challenge being the establishment of an effective stem cell administration route. This study assessed the antifibrogenic effects of adipose-derived stem cells (ASCs) in a liver fibrosis mouse model, focusing on 2 methods of delivery: intravenous injection and scaffold implantation. An extracellular matrix mimic scaffold was utilized for culturing peroxisome proliferator-activated receptor gamma coactivator 1-alpha–overexpressing ASCs (tASCs). These scaffolds, laden with tASCs, were then implanted subcutaneously in mice exhibiting liver fibrosis. In contrast, the Cell groups received biweekly intravenous injections of tASCs for 4 weeks. After 4 weeks, tissue samples were harvested from the euthanized mice for subsequent analysis. Real-time PCR and Western blot analyses on liver tissues, focusing on markers like alpha-smooth muscle actin (α-SMA), matrix metalloproteinase-2, and transforming growth factor-beta 1 (TGF-β1), showed that both delivery routes substantially lowered fibrotic and inflammatory markers compared to controls (P < 0.05), with no significant differences between the routes. Histological examinations, along with immunohistochemical analysis of α-SMA, collagen type I alpha, and TGF-β1, revealed that the scaffold implantation approach resulted in a greater reduction in fibrosis and lower immunoreactivity for fibrotic markers than intravenous delivery (P < 0.05). These findings indicate that delivering tASCs via a scaffold could be more effective, or at least similarly effective, in treating liver fibrosis compared to intravenous delivery. Scaffold implantation could offer a beneficial alternative to frequent intravenous treatments, suggesting its potential utility in clinical applications for liver disease treatment.
- 1 January 2025
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 108 (3) , 186-197
Open AccessScaffold implantation vs. intravenous delivery: a comparative preclinical animal study evaluating peroxisome proliferator-activated receptor gamma coactivator 1-alpha adipose-derived stem cells in liver fibrosis treatment
Regenerative medicine is expected to offer an alternative to liver transplantation for treating liver diseases in the future, with one significant challenge being the establishment of an effective stem cell administration route. This study assessed the antifibrogenic effects of adipose-derived stem cells (ASCs) in a liver fibrosis mouse model, focusing on 2 methods of delivery: intravenous injection and scaffold implantation. An extracellular matrix mimic scaffold was utilized for culturing peroxisome proliferator-activated receptor gamma coactivator 1-alpha–overexpressing ASCs (tASCs). These scaffolds, laden with tASCs, were then implanted subcutaneously in mice exhibiting liver fibrosis. In contrast, the Cell groups received biweekly intravenous injections of tASCs for 4 weeks. After 4 weeks, tissue samples were harvested from the euthanized mice for subsequent analysis. Real-time PCR and Western blot analyses on liver tissues, focusing on markers like alpha-smooth muscle actin (α-SMA), matrix metalloproteinase-2, and transforming growth factor-beta 1 (TGF-β1), showed that both delivery routes substantially lowered fibrotic and inflammatory markers compared to controls (P < 0.05), with no significant differences between the routes. Histological examinations, along with immunohistochemical analysis of α-SMA, collagen type I alpha, and TGF-β1, revealed that the scaffold implantation approach resulted in a greater reduction in fibrosis and lower immunoreactivity for fibrotic markers than intravenous delivery (P < 0.05). These findings indicate that delivering tASCs via a scaffold could be more effective, or at least similarly effective, in treating liver fibrosis compared to intravenous delivery. Scaffold implantation could offer a beneficial alternative to frequent intravenous treatments, suggesting its potential utility in clinical applications for liver disease treatment.
- Open Access
- 24 November 2022
- Published by Korean Liver Transplantation Society in Annals of Liver Transplantation
- Vol. 2 (2) , 132-138
Experience of split liver transplantation from deceased marginal donor: eight adult recipients from four deceased donors
Young Kyoung You, Jinha Chun, Yoonyoung Choi, Yoonkyoung Woo, Joseph Ahn, Ho Joong Choi. Ann Liver Transplant -0001;0:. https://doi.org/10.52604/alt.22.0018
- 24 November 2022
- Published by Korean Liver Transplantation Society in Annals of Liver Transplantation
- Vol. 2 (2) , 132-138
Open AccessExperience of split liver transplantation from deceased marginal donor: eight adult recipients from four deceased donors
Young Kyoung You, Jinha Chun, Yoonyoung Choi, Yoonkyoung Woo, Joseph Ahn, Ho Joong Choi. Ann Liver Transplant -0001;0:. https://doi.org/10.52604/alt.22.0018
- 28 January 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (2) , 443-449
Steroid-Resistant Rejection in Liver Transplant: A Single-Center Study for Risk Factor and Second-Line Treatment
- 28 January 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (2) , 443-449
Steroid-Resistant Rejection in Liver Transplant: A Single-Center Study for Risk Factor and Second-Line Treatment
- 26 January 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (2) , 374-379
Noninvasive Evaluations to Estimate Graft Steatosis in Living Donor Liver Transplant for Donor Safety and Successful Outcome
- 26 January 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (2) , 374-379
Noninvasive Evaluations to Estimate Graft Steatosis in Living Donor Liver Transplant for Donor Safety and Successful Outcome
- 20 January 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (2) , 412-417
A Single Center Experience of the Prognosis After Liver Transplantation From Discarded Graft Due to Poor Graft Conditions in Prioritized Centers
- 20 January 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (2) , 412-417
A Single Center Experience of the Prognosis After Liver Transplantation From Discarded Graft Due to Poor Graft Conditions in Prioritized Centers
- 15 January 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (2) , 424-429
Clinical Analysis of Factors Affecting Hospital Mortality After Liver Transplant in Patients With High Model for End-Stage Liver Disease Score
- 15 January 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (2) , 424-429
Clinical Analysis of Factors Affecting Hospital Mortality After Liver Transplant in Patients With High Model for End-Stage Liver Disease Score
- 15 January 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (2) , 380-385
Analysis of Prognostic Factors for Patients Undergoing Renal Replacement Therapy With Acute Kidney Injury Prior to Living Donor Liver Transplantation
- 15 January 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (2) , 380-385
Analysis of Prognostic Factors for Patients Undergoing Renal Replacement Therapy With Acute Kidney Injury Prior to Living Donor Liver Transplantation
- Open Access
- 29 August 2020
- Published by Wiley in FEBS Open Bio
- Vol. 11 (1) , 61-74
PGC‐1α is downregulated in a mouse model of obstructive cholestasis but not in a model of liver fibrosis
Several studies have indicated that cholestatic liver damage involves mitochondria dysfunction. However, the precise mechanism by which hydrophobic bile salts cause mitochondrial dysfunction is not clear. In this study, we intended to determine the pathogenesis of cholestatic liver injury associated with peroxisome proliferator‐activated receptor‐γ co‐activator 1α (PGC‐1α). A mouse model of cholestatic liver disease was generated by surgical ligation of the bile duct (BDL), and a mouse model of fibrosis was developed through serial administration of thioacetamide. After obtaining liver specimens on scheduled days, we compared the expression of the antioxidant enzymes (superoxide dismutase 2 [SOD2], catalase, and glutathione peroxidase‐1[GPx‐1]) and PGC‐1α in livers from mice with fibrosis and cholestasis using western blotting, immunohistochemistry, and immunofluorescence. We found that cholestatic livers exhibit lower expression of antioxidant enzymes, such as SOD2, catalase, and PGC‐1α. In contrast, fibrotic livers exhibit higher expression of antioxidant enzymes and PGC‐1α. In addition, cholestatic livers exhibited significantly lower expression of pro‐apoptotic markers (Bax) as compared to fibrotic livers. It is well known that overexpression of PGC‐1α increases mitochondrial antioxidant enzyme expression, and vice versa. Thus, we concluded that obstructive cholestasis decreases expression of PGC‐1α, which may lead to decreased expression of mitochondrial antioxidant enzymes, thereby rendering mice with cholestatic livers vulnerable to ROS‐induced cell death.
- 29 August 2020
- Published by Wiley in FEBS Open Bio
- Vol. 11 (1) , 61-74
Open AccessPGC‐1α is downregulated in a mouse model of obstructive cholestasis but not in a model of liver fibrosis
Several studies have indicated that cholestatic liver damage involves mitochondria dysfunction. However, the precise mechanism by which hydrophobic bile salts cause mitochondrial dysfunction is not clear. In this study, we intended to determine the pathogenesis of cholestatic liver injury associated with peroxisome proliferator‐activated receptor‐γ co‐activator 1α (PGC‐1α). A mouse model of cholestatic liver disease was generated by surgical ligation of the bile duct (BDL), and a mouse model of fibrosis was developed through serial administration of thioacetamide. After obtaining liver specimens on scheduled days, we compared the expression of the antioxidant enzymes (superoxide dismutase 2 [SOD2], catalase, and glutathione peroxidase‐1[GPx‐1]) and PGC‐1α in livers from mice with fibrosis and cholestasis using western blotting, immunohistochemistry, and immunofluorescence. We found that cholestatic livers exhibit lower expression of antioxidant enzymes, such as SOD2, catalase, and PGC‐1α. In contrast, fibrotic livers exhibit higher expression of antioxidant enzymes and PGC‐1α. In addition, cholestatic livers exhibited significantly lower expression of pro‐apoptotic markers (Bax) as compared to fibrotic livers. It is well known that overexpression of PGC‐1α increases mitochondrial antioxidant enzyme expression, and vice versa. Thus, we concluded that obstructive cholestasis decreases expression of PGC‐1α, which may lead to decreased expression of mitochondrial antioxidant enzymes, thereby rendering mice with cholestatic livers vulnerable to ROS‐induced cell death.
- Open Access
- 1 June 2020
- Published by Elsevier in Gastroenterology
- Vol. 158 (8) , 2033-2036.e4
The Path to Gastroenterology Leadership: The Preparation, the Process, and Achieving Success
- 1 June 2020
- Published by Elsevier in Gastroenterology
- Vol. 158 (8) , 2033-2036.e4
Open AccessThe Path to Gastroenterology Leadership: The Preparation, the Process, and Achieving Success
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Korean Medical Science
- Vol. 34 (45) , e273
Isolation of Secretome with Enhanced Antifibrotic Properties from miR-214-Transfected Adipose-Derived Stem Cells
Park JH, et al. J Korean Med Sci. 2019 Oct;34(45):e273. https://doi.org/10.3346/jkms.2019.34.e273
- 1 January 2019
- Published by XMLink in Journal of Korean Medical Science
- Vol. 34 (45) , e273
Open AccessIsolation of Secretome with Enhanced Antifibrotic Properties from miR-214-Transfected Adipose-Derived Stem Cells
Park JH, et al. J Korean Med Sci. 2019 Oct;34(45):e273. https://doi.org/10.3346/jkms.2019.34.e273